The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.
Following an extensive, nationwide search, Goldie Taylor has been named Senior Vice President, Chief Communication and Marketing Officer at Dana-Farber Cancer Institute.
The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.
When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.
Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.
The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.
As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.
The European Commission has granted conditional marketing authorization to sotorasib for the treatment of adult patients with KRAS G12C mutant advanced non–small cell lung cancer.
The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6 inhibitor, and who have AR staining of 40% or more in cancer tissue.
New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer relevant genes
Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.
It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.
Black men with localized prostate cancer who had been treated with definitive radiotherapy had a lower likelihood of experiencing biochemical recurrence, distant metastasis, and prostate cancer–specific mortality compared with White men despite having more aggressive disease.
David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.
One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.
No dose-limiting toxicities have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat and hydroxychloroquine in the dose-escalation portion of the ongoing phase 1/2 APOLLO 613 trial.
CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.
Kim A. Reiss Binder, MD, discusses the rationale behind the first-in-human study of adenovirally transduced anti-HER2 CAR-Ms and where the research will be heading in the future.
The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.
Zangmeister Cancer Center, an American Oncology Network, LLC partner practice, is pleased to announce the opening of its new cancer center in Grove City, Ohio at 5500 N. Meadows Drive, Suite 230.
The combination of pembrolizumab and pepinemab showcased encouraging safety and tolerability when given as first-line treatment in patients with advanced, recurrent, or metastatic head and neck squamous cell carcinoma.
The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer and other malignancies.
Charu Aggarwal, MD, MPH, shares how to navigate the nuances of molecular testing in non–small cell lung cancer, key developments made in the treatment of those whose tumors harbor actionable mutations, and the role of PD-L1 expression in informing clinical decisions.
CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.
Melissa Geller, MD, MS, and colleagues discuss key clinical trials that have changed the landscapes of HER2-positive breast cancer and triple-negative breast cancer, the role of first- and second-line maintenance therapy in ovarian cancer, and key updates in cervical and endometrial cancers.
The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.
Adjuvant chemotherapy with modified fluoropyrimidine, leucovorin, and oxaliplatin improved disease-free survival among patients with liver-only metastases from colorectal cancer who were treated with hepatectomy.
New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.
The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.
